Glen Burkhardt - PhaseBio Pharmaceuticals VP HR
Insider
Glen Burkhardt is VP HR of PhaseBio Pharmaceuticals
| Age | 64 |
| Phone | 610 981 6500 |
| Web | https://phasebio.com |
PhaseBio Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.0607) % which means that it has lost $1.0607 on every $100 spent on assets. This is way below average. PhaseBio Pharmaceuticals' management efficiency ratios could be used to measure how well PhaseBio Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.PhaseBio Pharmaceuticals has accumulated 1.36 M in total debt. PhaseBio Pharmaceuticals has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PhaseBio Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, PhaseBio Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PhaseBio Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PhaseBio to invest in growth at high rates of return. When we think about PhaseBio Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 3 records | INSIDER Age | ||
| PharmD Young | Processa Pharmaceuticals | 72 | |
| Robert Floyd | Processa Pharmaceuticals | 68 | |
| PharmD Bigora | Processa Pharmaceuticals | 65 | |
Management Performance
| Return On Asset | -1.06 |
PhaseBio Pharmaceuticals Leadership Team
Elected by the shareholders, the PhaseBio Pharmaceuticals' board of directors comprises two types of representatives: PhaseBio Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PhaseBio. The board's role is to monitor PhaseBio Pharmaceuticals' management team and ensure that shareholders' interests are well served. PhaseBio Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PhaseBio Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan MBA, CEO Pres | ||
| Susan Arnold, VP Operations | ||
| Lawrence Perkins, Chief Officer | ||
| Jonathan Birchall, Chief Officer | ||
| Kristopher Hanson, Gen SVP | ||
| Lauren Richardson, Global Assurance | ||
| Glen Burkhardt, VP HR | ||
| John CPA, Chief Officer |
PhaseBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PhaseBio Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.06 | |||
| Operating Margin | (127.39) % | |||
| Current Valuation | (1.26 M) | |||
| Shares Outstanding | 49.86 M | |||
| Shares Owned By Insiders | 6.72 % | |||
| Shares Owned By Institutions | 25.02 % | |||
| Number Of Shares Shorted | 2.07 M | |||
| Price To Book | 26.18 X | |||
| Price To Sales | 1.58 X | |||
| Revenue | 10.83 M |
Pair Trading with PhaseBio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PhaseBio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PhaseBio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |